Adipotide (FTPP) is a cyclic proapoptotic peptidomimetic combining a prohibitin-homing motif (CKGGRAKDC) with a D-enantiomeric mitochondrial-disrupting domain, studied in preclinical white adipose vascular biology.
Scientific Profile & Research Key Points: Adipotide
Adipotide (FTPP) is a cyclic proapoptotic peptidomimetic combining a prohibitin-homing motif (CKGGRAKDC) with a D-enantiomeric mitochondrial-disrupting domain, studied in preclinical white adipose vascular biology.
Active Batch Release Specifications (Lot SL-2026-104)
Analytical release verification for current Adipotide (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-104 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water or sterile saline (0.9% NaCl)
Temperature & Stability
Store lyophilized vial at -20°C shielded from light; preserve Cys1–Cys9 disulfide bond by avoiding reducing agents.
Adipotide — Technical Questions & Answers
What is the molar concentration when reconstituting Adipotide (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of Adipotide (MW 2555.20 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 0.98 mM (978 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does Adipotide's counterion stoichiometry affect assay mass calculations?
Adipotide (CAS 859216-15-2, formula C111H204N36O28S2) is supplied as Acetate / TFA lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify Adipotide Lot SL-2026-104 and what pathway does it target?
Lot SL-2026-104 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 2555.20 g/mol. In preclinical literature, Adipotide targets Prohibitin (PHB) on white adipose vasculature (Barnhart K.F. et al., Sci Transl Med (2011) — Peptidomimetic targeting of white adipose vasculature (PMID: 22072636)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Biochemical comparison of long-acting amylin analogue Cagrilintide (AM833) against triple incretin agonist Retatrutide and dual-pathway Cagrilintide + Semaglutide combinations.
Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Comparative receptor pharmacology of Survodutide (BI 456906), Mazdutide (IBI362), and Retatrutide (LY3437943): GLP-1R/GCGR/GIPR potency ratios and stability.
Related Metabolic & Incretin Research Compounds
View category →